c-MET as a potential therapeutic target and biomarker in cancer

Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

(2017) J. H. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells

(2015) Roya Navab et al.   NEOPLASIA

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer

(2011) Takashi Kijima et al.   CANCER SCIENCE

Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer

(2011) Shingo Kato et al.   CANCER SCIENCE

Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis

(2011) Guro Aune et al.   GYNECOLOGIC ONCOLOGY

Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells

(2011) Ran Qiang et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative Phospho-Proteomic Profiling of Hepatocyte Growth Factor (HGF)-MET Signaling in Colorectal Cancer

(2011) Shawna L. Organ et al.   JOURNAL OF PROTEOME RESEARCH

Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer

(2011) Francesca De Bacco et al.   JNCI-Journal of the National Cancer Institute

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient

(2011) Sohei Yamamoto et al.   MODERN PATHOLOGY

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

(2011) P. Y. Wen et al.   NEURO-ONCOLOGY

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

(2011) Nicole G Chau et al.   Head and Neck Optical Diagnostics Society

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor

(2010) B.-S. Pan et al.   CANCER RESEARCH

MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity

(2010) J. W. Tyner et al.   CANCER RESEARCH

Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency

(2010) U. McDermott et al.   CANCER RESEARCH

MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors

(2010) V. Cepero et al.   CANCER RESEARCH

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

(2010) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

(2010) M. S. Gordon et al.   CLINICAL CANCER RESEARCH

The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer

(2010) T. John et al.   CLINICAL CANCER RESEARCH

Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis

(2010) V. Cepero et al.   CURRENT PHARMACEUTICAL DESIGN

Small molecule c-Met kinase inhibitors: a review of recent patents

(2010) John Porter   EXPERT OPINION ON THERAPEUTIC PATENTS

American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section

(2010) Patrick Y Wen   Expert Review of Anticancer Therapy

MET mutations in cancers of unknown primary origin (CUPs)

(2010) Giulia M. Stella et al.   HUMAN MUTATION

Plexin B1 Suppresses c-Met in Melanoma: A Role for Plexin B1 as a Tumor-Suppressor Protein through Regulation of c-Met

(2010) Laurel Stevens et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Clinical value of plasma hepatocyte growth factor measurement for the diagnosis of periampullary cancer and prognosis after pancreaticoduodenectomy

(2010) Omar Barakat et al.   JOURNAL OF SURGICAL ONCOLOGY

Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status

(2010) Takamitsu Onitsuka et al.   Journal of Thoracic Oncology

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

(2010) Heounjeong Go et al.   Journal of Thoracic Oncology

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

(2010) J Rafael Sierra et al.   Molecular Cancer

Roles of Sema4D and Plexin-B1 in tumor progression

(2010) Ewe Seng Ch'ng et al.   Molecular Cancer

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition

(2010) Simona Corso et al.   Molecular Cancer

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Search for Quark Compositeness with the Dijet Centrality Ratio inppCollisions ats=7  TeV

(2010) V. Khachatryan et al.   PHYSICAL REVIEW LETTERS

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

(2009) T. Y. Seiwert et al.   CANCER RESEARCH

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

(2009) F. Qian et al.   CANCER RESEARCH

HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

(2009) L. M. Knowles et al.   CLINICAL CANCER RESEARCH

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Expression of Hepatocyte Growth Factor and Its Receptor Met in Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development

(2009) R. Vuononvirta et al.   CLINICAL CANCER RESEARCH

Multitarget drugs: the present and the future of cancer therapy

(2009) Annalisa Petrelli et al.   EXPERT OPINION ON PHARMACOTHERAPY

Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients

(2009) Yuji Toiyama et al.   INTERNATIONAL JOURNAL OF CANCER

Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin

(2009) L. Capparuccia et al.   JOURNAL OF CELL SCIENCE

IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

(2009) Federico Cappuzzo et al.   JOURNAL OF CLINICAL ONCOLOGY

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

(2009) Michèle Beau-Faller et al.   Journal of Thoracic Oncology

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

(2009) Takamitsu Onitsuka et al.   LUNG CANCER

Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells

(2009) G M Argast et al.   ONCOGENE

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

(2009) Hua-Jun Chen et al.   PATHOLOGY & ONCOLOGY RESEARCH

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

(2008) F. Cappuzzo et al.   ANNALS OF ONCOLOGY

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

(2008) Zhao-Shi Zeng et al.   CANCER LETTERS

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH

"Active" Cancer Immunotherapy by Anti-Met Antibody Gene Transfer

(2008) E. Vigna et al.   CANCER RESEARCH

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

(2008) Katsuhiro Okuda et al.   CANCER SCIENCE

Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells

(2008) Isolde Seiden-Long et al.   CARCINOGENESIS

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

(2008) L. Toschi et al.   CLINICAL CANCER RESEARCH

Molecular cancer therapy: Can our expectation be MET?

(2008) Cristina Migliore et al.   EUROPEAN JOURNAL OF CANCER

Expression and mutational analysis ofMETin human solid cancers

(2008) Patrick C. Ma et al.   GENES CHROMOSOMES & CANCER

Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages

(2008) Jose Rafael Sierra et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA